CG Oncology’s late-stage bladder cancer treatment notched a complete response in roughly three-quarters of treated patients, fueling optimism that the company’s Wall Street success story is no fluke.
IRVINE, Calif.--(BUSINESS WIRE)--CG Oncology, Inc. announced today that it has entered into a clinical trial collaboration agreement to evaluate the combination of CG Oncology’s investigational ...
CG Power shares surged nearly 10% as strong Q3 results, a robust ₹15,750-crore order book and EU market access boosted ...
IRVINE, Calif.--(BUSINESS WIRE)--CG Oncology, Inc. (Nasdaq: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing ...
CG Oncology announced the initiation of a rolling Biologics License Application submission to the U.S. FDA for cretostimogene, its therapy targeting high-risk BCG-unresponsive non-muscle invasive ...
When it comes to golf club technology, the term “center of gravity” — “CG” or “CoG” for short — gets thrown around quite a bit, but it isn’t often explained to the average golf consumer. While CG may ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results